When was LianBio founded?

LianBio was founded in 1999 and raised its 1st funding round 21 years after it was founded.

Where is LianBio located?

LianBio is headquartered in Shanghai, China.

How many employees does LianBio have?

As of Mar 01, 2026, the latest employee count at LianBio is 50 - 199.

Is LianBio a funded company?

LianBio is a funded company, having raised a total of $313M across 2 funding rounds to date. The company's 1st funding round was a $***** Unattributed round, raised on Oct 29, 2020.

When was the latest funding round of LianBio?

LianBio's latest funding was a $***** Unattributed round on Apr 05, 2021, with participation from 0 investor. Its primary sector is Oncology. In China, the Oncology sector has seen $765M in funding in 2026 to date.

Where does LianBio rank among its competitors?

LianBio ranks 844th amongst 3393 active competitors, of which 1152 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of LianBio?

LianBio's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Immuneel secured the most recent funding round in June, 2026.

LianBio - 2026 Company Profile, Team, Funding, Competitors & Financials

LianBio is a public company based in Shanghai (China), founded in 1999. It operates as a Developer of therapeutics for cardiorenal and oncology diseases. LianBio has raised $313M in funding from investors like Venrock, RA Capital Management and SDIC. The company has 3393 active competitors, including 1152 funded and 805 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences.

Company Details

Developer of therapeutics for cardiorenal and oncology diseases. The company is involved in the development of its candidate Infigratinib (BGJ398) which is orally administered FGFR1-3 tyrosine kinase inhibitor and can be used in FGFR-driven diseases, like cholangiocarcinoma and urothelial carcinoma. Other lead candidate is BBP-398 which is an allosteric SHP2 inhibitor for wild-type SHP2, used in the treatment of tumors having SHP2 activity and Mavacamten is used in the treatment of cardiac contractility.

Key Metrics

Founded Year

1999

Location

Shanghai, China

Stage

Public

Total Funding

$313M in 2 rounds

Latest Funding Round

Unattributed, Apr 05, 2021, $*****

Investors

Venrock & 14 more

Ranked

844^th among 3393 active competitors

Employee Count

50 - 199 as on Mar 01, 2026

Similar Companies

Jazz Pharmaceuticals & 3128 more

Exit Details

Public

View LianBio's full profile

LianBio is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
LIANBIO CIN: 1831283 , United States, Active	Dec 15, 2019	-	-	-

LianBio got listed on Nov 01, 2021.

Click here to take a look at LianBio's IPO in detail

LianBio has raised a total funding of $313M over 2 rounds. Its first funding round was on Oct 29, 2020. LianBio has 15 institutional investors.

Here is the list of recent funding rounds of LianBio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 05, 2021	4842120	Unattributed	7531571	3594906	7347096	6374901
Oct 29, 2020	9413508	Unattributed	1556602	7564069	RA Capital Management & 2 more	Casdin Capital & 10 more

Access funding benchmarks and valuations. Sign up today!

View details of LianBio's funding rounds and investors

LianBio's employee count trend

LianBio has 50 - 199 employees as of Mar 26. Here is LianBio's employee count trend over the years:

Uncover LianBio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of LianBio include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of LianBio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 17 others	74/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Domain Associates, Fidelity Investments & 19 others	72/100
7th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
844th	LianBio 1999, Shanghai (China), Public	Developer of therapeutics for cardiorenal and oncology diseases	$313M	T. Rowe Price, BlackRock & 13 others	44/100